Dyne Therapeutics, Inc. (DYN) SEC Filings & Earnings Calls

Data from pooled dose group includes mixed doses; only 8 of 26 received registrational dose for full 12 months

“only 8 of 26 participants in the pooled dose group received the registrational dose for the full 12 months analyzed” · word for word

Topline data from REC expected Q1 2027; regulatory risk remains

“topline data in Q1 2027 from the ACHIEVE registrational expansion cohort” · word for word

Cash burn and need for additional funding

“we will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.” · word for word

Clinical development risk

“our product candidates are in varying stages of preclinical and clinical development, and we have not completed clinical development of any product candidate.” · word for word

Unproven platform

“our approach to the discovery and development of product candidates based on our FORCE platform is unproven, and we may not be successful in our efforts to develop our product candidates.” · word for word

Debt covenant compliance

“our Loan Agreement contains restrictive and financial covenants that may limit our operating flexibility and our failure to comply with the covenants or other terms of the Loan Agreement... could result in a default under the Loan Agreement that could materially and adversely affect our business.” · word for word

Clinical and regulatory risk: potential delays in BLA approval or trial outcomes.

“PDUFA target action date set for January 21, 2027; topline data from ACHIEVE REC planned for Q1 2027.” · word for word

High cash burn rate: R&D expenses increased 53% YoY.

“R&D expenses were $152.2 million for Q2 2026 vs $99.2 million for Q2 2025.” · word for word

Dilution from offering; 18.3M shares plus option

“18,300,000 shares ... option to purchase up to an additional 2,745,000 shares”

Regulatory approval risk; clinical trial and commercialization uncertainties

“Forward-looking statements highlight risks in FDA interpretation of data, cash sufficiency, and development uncertainties.”

Increased debt obligations may raise financial risk, though covenant eased.

“The Second Amendment... reduced the minimum cash covenant under the Loan Agreement.”

Clinical and regulatory risk: topline data expected Q1 2027; Accelerated Approval not guaranteed.

“Potential BLA submission for U.S. Accelerated Approval in Q3 2027; launch expected H1 2028 if Priority Review granted.”

Clinical and regulatory risk; BLA approval not guaranteed.

“Potential launch depends on FDA approval and Priority Review.”

High cash burn rate; R&D expenses $100.9M per quarter.

“R&D expenses $100.9 million in Q1 2026.”

Need for substantial additional funding

“We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts;” · word for word

Clinical trial failure risk

“we may encounter substantial delays in commencement, enrollment or completion of our clinical trials and the data from the clinical trials of our product candidates may fail to demonstrate sufficient safety and efficacy to warrant further development or satisfy the applicable regulatory authorities, which could prevent us from commercializing any product can” · word for word

Unproven platform technology

“our approach to the discovery and development of product candidates based on our FORCE platform is unproven, and we may not be successful in our efforts to develop our product candidates;” · word for word

Debt covenant compliance risk

“our Loan Agreement contains restrictive and financial covenants that may limit our operating flexibility and our failure to comply with the covenants or other terms of the Loan Agreement, including as a result of events beyond our control, could result in a default under the Loan Agreement that could materially and adversely affect our business;” · word for word

Clinical-stage company with no approved products

“We are a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. Our product candidates are in varying stages of preclinical and clinical development, and we have not completed clinical development of any product candidate or commercialized any product candidate to date.” · word for word

Potential dilution from authorized share increase

“To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares.” · word for word

Key executive turnover

“Richard Scalzo, our former Senior Vice President, Head of Finance and Administration who ceased serving as our Senior Vice President, Head of Finance and Administration on March 31, 2025” · word for word

Clinical-stage company with no approved products or revenue; dependent on successful clinical trials and regulatory approvals.

“clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases” · word for word

Drug pricing regulation risk

“The IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap.” · word for word

Clinical and regulatory failure risk

“We may never succeed in obtaining regulatory approval for any product candidate we may develop.” · word for word

Clinical and regulatory risks; pipeline success not guaranteed.

“Forward-looking statements highlight uncertainties in clinical trials and regulatory approvals.”

Dilution risk from new shares; potential overhang if option exercised.

“18,980,478 shares offered; option for additional 2,847,071 shares.”

Regulatory risk: FDA may not grant accelerated approval; competition from other DMD therapies.

“BLA submission planned for Q2 2026; approval not guaranteed.”

Debt service obligations; interest rate risk (floating rate); collateral includes IP.

“Interest at prime + 2.45% (floor 7.50%); secured by substantially all assets including IP.”

Clinical trial failure risk

“Our product candidates are in varying stages of preclinical and clinical development, and we have not completed clinical development of any product candidate.” · word for word

Funding dependency

“We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.” · word for word

Debt covenant risk

“Our loan agreement with Hercules contains restrictive and financial covenants that may limit our operating flexibility and our failure to comply with the covenants or other terms of the loan agreement, including as a result of events beyond our control, could result in a default under the loan agreement that could materially and adversely affect our business” · word for word

Clinical trial enrollment delay for DM1 program

“ACHIEVE trial enrollment completion delayed from Q4 2025 to early Q2 2026”

Pre-revenue biotech with no approved products; all value depends on clinical and regulatory success

“Clinical-stage company with no commercial revenue; relies on pipeline success”